Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

View source ↗

Summary

A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymphomas. The study incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Follicular Lymphoma

Drugs mentioned

• CD19 CAR-T expressing IL7 and CCL19

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Status: COMPLETED